Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Arena Says Patient Programs Will Offset Belviq’s Premium Price For Some

This article was originally published in The Pink Sheet Daily

Executive Summary

The obesity pill will be priced at a slight premium to Vivus’ rival drug Qsymia, but Arena CEO says the amount patients will actually pay will vary based on coupon and rebate programs.


Related Content

Vivus Beefs Up Qsymia Efforts As Eisai Prepares To Launch Belviq
Belviq Gains FDA Approval For Weight Loss, But DEA Review Will Delay Launch
Arena Scores Hefty Obesity Drug Deal With Eisai Ahead Of PDUFA Date


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts